Federally-Listed PSOs

Below is a list of PSOs that are currently listed by AHRQ. A health care provider can only obtain the confidentiality and privilege protections of the Patient Safety Act by working with a Federally-listed PSO.

Use the categories on the left to filter the list of PSOs or search a PSO name.

Note: AHRQ updates the PSO information contained within the directories weekly, as needed; changes are made when there are newly listed PSOs and/or when existing information requires revision. Changes that would otherwise be effective on a weekend day or holiday will be effective on the next business day. Information contained in the directories is based on attestations that the PSOs provide. To update PSO contact information, please use the Change of Listing Information form; to update profile information, please go to the PSO PPC Web site.

There are 94 total PSOs listed by AHRQ.

PLEASE NOTE: To search for a PSO by State, use the 2 letter state abbreviation. Example: Kansas = KS

HCA Patient Safety Organization, LLC - P0157
Component of Parent Org(s):
  • HCA Holdings, Inc. (direct parent: EP Holdco, LLC)
Effective Date and Time of Initial Listing: April 9, 2014 12:01 AM ET
PSO Mailing Address: P.O. Box 750, Nashville, TN 37202
PSO Phone Number: 615-344-2293
Point of Contact: Rhonda Kaye Kollenborn
Point of Contact Phone: 615-344-5372
Point of Contact Email: Rhonda.Kollenborn@hcahealthcare.com (link is external)
Two Bona Fide Contract Requirement: Next attestation period is 04/09/2020 through 04/08/2022
Disclosures & Finding: None
Subject to FDA-Regulated Reporting Entity Guidance: No
Vizient™ PSO - P0007
Component of Parent Org(s):
  • Vizient Inc
Effective Date and Time of Initial Listing: November 5, 2008 12:01 AM ET
PSO Mailing Address: 155 North Wacker Drive, 40th floor, Chicago, IL 60606
PSO Phone Number: 312-775-4100
Point of Contact: Ellen M. Flynn RN, MBA, JD
Point of Contact Phone: 312-775-4100
Point of Contact Email: Ellen.Flynn@vizientinc.com (link is external)
Two Bona Fide Contract Requirement: Next attestation period is 11/05/2020 through 11/04/2022
Disclosures & Finding: None
Subject to FDA-Regulated Reporting Entity Guidance: No